Sugi Predict

Sugi Predict / Compounds / SCHEMBL295891

SCHEMBL295891

SCHEMBL295891

COc1cc2ncnc(Cl)c2cc1OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ENPP1 P22413 3/20 0.68
▸ KDM1A O60341 1/20 0.58
▸ EGFR P00533 9/20 0.57
▸ HTT P42858 2/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ IRAK1 P51617 1/20 0.57
▸ IRAK4 Q9NWZ3 1/20 0.57
▸ LCK P06239 1/20 0.56
▸ MAPK1 P28482 2/20 0.55
▸ ACHE P22303 1/20 0.54
▸ BACE1 P56817 1/20 0.54
▸ KIT P10721 1/20 0.54
▸ ATM Q13315 1/20 0.53
▸ RAF1 P04049 1/20 0.52
▸ RET P07949 1/20 0.51
▸ KDR P35968 1/20 0.51
▸ ELANE P08246 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297514 1.00 ENPP1 (0.68) ENPP1KDM1AEGFRHTTKDM4E
SCHEMBL29631520 1.00 ENPP1 (0.68) ENPP1KDM1AEGFRHTTKDM4E
Hydrochloric Acid SCHEMBL28102763 0.99 ENPP1 (0.67) ENPP1KDM1AEGFRHTTKDM4E
Hydrochloric Acid SCHEMBL156332 0.99 ENPP1 (0.67) ENPP1KDM1AEGFRHTTKDM4E
Hydrochloric Acid SCHEMBL28041015 0.99 ENPP1 (0.67) ENPP1KDM1AEGFRHTTKDM4E
SCHEMBL8857758 0.93 ENPP1 (0.56) ENPP1KDM1AEGFRHTTKDM4E
SCHEMBL1781406 0.91 ENPP1 (0.56) ENPP1KDM1AEGFRHTTKDM4E
SCHEMBL7205078 0.88 ENPP1 (0.67) ENPP1KDM1AEGFRHTTIRAK1
SCHEMBL16760397 0.86 KDR (0.67) ENPP1KDM1AEGFRHTTKDM4E
SCHEMBL10296331 0.85 IRAK1 (0.68) KDM1AEGFRHTTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262822-A1 WDR5 INHIBITORS AND MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-08-08 — — US disclosed
EP-4334305-A1 WDR5 INHIBITORS AND MODULATORS Vanderbilt University (US) 2024-03-13 — — EP disclosed
CN-112996784-B Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2023-05-30 — — CN disclosed
WO-2022236101-A1 WDR5 INHIBITORS AND MODULATORS VANDERBILT UNIVERSITY (US) 2022-11-10 — — WO disclosed
CN-112996784-A Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2021-06-18 — — CN disclosed
WO-2020057403-A1 INDOLE DERIVATIVE AND MEDICAL APPLICATION THEREOF 北京越之康泰生物医药科技有限公司 2020-03-26 — — WO disclosed
WO-2020057403-A1 INDOLE DERIVATIVE AND MEDICAL APPLICATION THEREOF 北京越之康泰生物医药科技有限公司 2020-03-26 — — WO disclosed
WO-2019071351-A1 NOVEL FLUORINATED 4-ARYLOXYQUINAZOLINE DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2019-04-18 — — WO disclosed
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORP. (US) 2018-08-21 — — US disclosed
EP-2268623-B9 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2018-02-28 — — EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 — — US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 — — US disclosed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 — — US disclosed
EP-1474420-A1 QUINAZOLINE COMPOUNDS Astrazeneca AB (SE) 2004-11-10 — — EP disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 — — US disclosed
US-6797823-B1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-09-28 — — US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 — — EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 — — EP disclosed
WO-2003064413-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2003-08-07 — — WO disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof BRAF, RAF1, ARAF ENPP1 1136/4885KDM1A 2134/4885EGFR 504/4885
US-20240262822-A1 WDR5 INHIBITORS AND MODULATORS WDR5, WDR1, WDR3 ENPP1 2745/4885KDM1A 437/4885EGFR 3758/4885
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents VEGFA, FLT4, FLT1 ENPP1 542/4885KDM1A 344/4885EGFR 1095/4885
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS ENPP1 2399/4885KDM1A 3317/4885EGFR 2705/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 ENPP1 2763/4885KDM1A 3950/4885EGFR 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.